← Search & browse all drugs

gadopentetic acid

V08CA01

Forms & Strengths

Intravenous solution: 469 mg/mL (0.5 mol/L)

Adult Dosing

MRI of brain or spine: 0.2 mmol/kg (0.2 mL/kg) administered intravenously as a rapid bolus
MRI of body: 0.1 to 0.2 mmol/kg administered intravenously as a rapid bolus
Maximum cumulative dose: 0.2 mmol/kg within a single diagnostic procedure

Pediatric Dosing

Neonates under 2 years: Safety and efficacy not established due to immature renal function
Pediatric patients 2 years and older: 0.1 to 0.2 mmol/kg administered intravenously as a rapid bolus for cranial and spinal MRI

Indications

Contrast-enhanced magnetic resonance imaging (MRI) of the brain and spinal cord in adults and pediatric patients aged 2 years and older
Contrast-enhanced MRI of the body (intra-cardiac, thoracic, pelvic, and retroperitoneal regions)

Mechanism of Action

Non-specific extracellular gadolinium-based contrast agent
Shortens the T1 and T2 relaxation times of protons in blood and tissues when placed in a magnetic field
Enhances the signal intensity (brightness) of well-vascularized tissues, lesions, and areas of disrupted blood-brain barrier

Contraindications

History of severe hypersensitivity reactions to gadopentetic acid or other gadolinium-based contrast agents
Patients with acute kidney injury or chronic severe renal failure (eGFR <30 mL/min/1.73m²)

Adverse Reactions

Injection site reactions (pain, coldness, warmth)
Nausea, vomiting, and altered taste
Headache, dizziness, and paresthesia
Hypersensitivity reactions ranging from mild urticaria to severe anaphylaxis
Nephrogenic Systemic Fibrosis (NSF) in patients with severe renal impairment

Drug Interactions

Concomitant use with drugs that impair renal function may increase the risk of nephrotoxicity and subsequent NSF
No formal pharmacokinetic drug-drug interaction studies have been conducted

Curated Content: Needs Vetting Before Put to Clinical Use